Authors
Yaming Li, Fang Zhang, Wei Liu, Xiuhai Su, Bin Zhou, Na Xu, Junjie Shang, Chen Fang, Liujun Fu, Fangqiong Li, Chao Zheng, Jinyou Duan
Published in
Diabetes, obesity & metabolism. Oct 02, 2026. Epub Oct 02, 2026.
Abstract
Crisugabalin (HSK16149), a selective γ-aminobutyric acid (GABA) analog, has shown preliminary efficacy in controlling diabetic peripheral neuropathic pain (DPNP), but efficacy in patients with inadequate response to prior pregabalin treatment remains unknown.
This multicentre randomized controlled trial was conducted from April 18, 2024 to July 18, 2024. Adults patients with DPNP and inadequate response to pregabalin were randomized at a 1:1 ratio to receive crisugabalin (40 mg/day) or pregabalin (300 mg/day) for 4 weeks. The primary endpoint was the mean change of SF-MPQ pain score from baseline to 4 weeks of treatment.
Ninety-three patients were randomized: 47 and 46 in the crisugabalin and pregabalin groups, respectively. The efficacy analysis included 90 patients (mean age, 58.9 years; 49 men). The least square mean (LSM) difference in the mean change of SF-MPQ pain score was -7.2 (95% CI: -12.4, -2.0; ANCOVA p = 0.007) between the two groups. The rate of treatment-emergent adverse events was 29.5% (13/44) and 47.8% (22/46) in the crisugabalin and pregabalin groups, respectively.
Treatment with crisugabalin 40 mg/day resulted in greater pain reduction in comparison to pregabalin 300 mg/day over a period of 4 weeks in DPNP patients with inadequate response to prior pregabalin treatment.
PMID:
42823911
Bibliographic data and abstract were imported from PubMed on 02 Oct 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 25
- Comments 0